Allergan Expands Access to IUDs for Millions of Underserved U.S. Women by Announcing Agreement with Apexus

September 10, 2015

Allergan plc, a leading global pharmaceutical company, has announced an agreement to make LILETTA® available to the safety-net provider locations that Apexus, the 340B Drug Pricing Program Prime Vendor, serves. The agreement provides LILETTA's discounted per-unit price to all public health clinics and organizations that participate in the 340B Prime Vendor Program (PVP) and expands access to IUDs for millions of underserved women throughout the United States who may not have been able to afford one.